Antibiotic resistance of bacterial biofilms

International Journal of Antimicrobial Agents

Volumn 35, Issue 4, 2010, Pages 322-332

  Høiby, Niels ^a,b   Bjarnsholt, Thomas ^a,b   Givskov, Michael ^b   Molin, Søren ^c   Ciofu, Oana ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Lactamase; Antibiotic resistance; Antibiotic tolerance; Biofilm; Cystic fibrosis; Efflux pumps; Foreign body infections; Mutators; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORNASE ALFA; GARLIC EXTRACT; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CELL DENSITY; CROSS INFECTION; CYSTIC FIBROSIS; DNA REPAIR; FOREIGN BODY; HORIZONTAL GENE TRANSFER; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; SHORT SURVEY; STAPHYLOCOCCUS INFECTION; UPREGULATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS;

EID: 77049122482     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.011     Document Type: Short Survey

References (112)

1. Costerton W., Veeh R., Shirtliff M., Pasmore M., Post C., and Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112 (2003) 1466-1477
2. Bjarnsholt T., Jensen P.Ø., Fiandaca M.J., Pedersen J., Hansen C.R., Andersen C.B., et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44 (2009) 547-558
3. Kolenbrander P.E., and Palmer Jr. R.J. Human oral bacterial biofilms. In: Ghannoum M.A., and O'Toole G.A. (Eds). Microbial biofilms (2004), ASM Press, Washington, DC
4. Høiby N., Döring G., and Schiøtz P.O. The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol 40 (1986) 29-53
5. Hall-Stoodley L., Hu F.Z., Gieseke A., Nistico A., Nguyen L., Hayes J., et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 296 (2006) 202-211
6. Sanderson A.R., Leid J.G., and Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 116 (2006) 1121-1126
7. Gristina A.G., Oga M., Webb L.X., and Hobgood C.D. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 228 (1985) 990-993
8. Trampuz A., and Zimmerli W. Prostetic joint infections: update in diagnosis and treatment. Swiss Med Wkly 135 (2005) 243-251
9. Del Pozo J.L., and Patel R. Infection associated with prostetic joints. N Engl J Med 361 (2009) 787-794
10. Taconelli E., Smith G., Hieke K., Lafuma A., and Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infection in intensive care units of four European countries: litterature- and registry-based estimates. J Hosp Infect 72 (2009) 97-103
11. Kirketerp-Møller K., Jensen P.Ø., Fazli M., Madsen K.G., Pedersen J., Moser C., et al. Distribution, and ecology of bacteria in chronic wounds. J Clin Microbiol 46 (2008) 2717-2722
12. Bjarnsholt T., Kirketerp-Møller K., Jensen P.Ø., Madsen K.G., Phipps R., Krogfelt K., et al. Why chronic wounds won't heal: a novel hypothesis. Wound Repair Regen 16 (2008) 2-10
13. Høiby N., Johansen H.K., Ciofu O., Jensen P.Ø., Bjarnsholt T., and Givskov M. Foreign body infections-biofilms and quorum sensing. Ugeskr Laeger 169 (2007) 4163-4166 [in Danish]
14. Wingender J., Strathmann M., Rode A., Leis A., and Flemming H.C. Isolation and biochemical characterization of extracellular polymeric substances from Pseudomonas aeruginosa. Methods Enzymol 336 (2001) 302-314
15. Whitchurch C.B., Tolker-Nielsen T., Ragas P.C., and Mattick J.S. Extracellular DNA required for bacterial biofilm formation. Science 295 (2002) 1487
16. Sternberg C., Christensen B.B., Johansen T., Nielsen A.T., Andersen J.B., Givskov M., et al. Distribution of bacterial growth activity in flow-chamber biofilms. Appl Environ Microbiol 65 (1999) 4108-4117
17. Klausen M., Heydorn A., Ragas P., Lambertsen L., Aaes-Jorgensen A., Molin S., et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol 48 (2003) 1511-1524
18. Heydorn A., Ersboll B., Kato J., Hentzer M., Parsek M.R., Tolker-Nielsen T., et al. Statistical analysis of Pseudomonas aeruginosa biofilm development: impact of mutations in genes involved in twitching motility, cell-to-cell signaling, and stationary-phase sigma factor expression. Appl Environ Microbiol 68 (2002) 2008-2017
19. Givskov M. Jamming the command language of bacteria: a new approach to the control of bacterial infections [Doctoral thesis]. Danish Technical University; 2005.
20. Marshall K.C. Biofilms: an overview of bacterial adhesion, activity, and control at surfaces. ASM News 58 (1992) 202-207
21. Webb J.S., Thompson L.S., James S., Charlton T., Tolker-Nielsen T., Koch B., et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 185 (2003) 4585-4592
22. Kobayashi N., Bauer T.W., Tuohy M.J., Fujishiro T., and Procop G.W. Brief ultrasonication improves detection of biofilm-formative bacteria around a metal implant. Clin Orthop Relat Res 475 (2007) 210-213
23. Anwar H., and Costerton J.W. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34 (1990) 1666-1671
24. Moskowitz S.M., Foster J.M., Emerson J., and Burns J.L. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42 (2004) 1915-1922
25. Bjarnsholt T., Kirketerp-Møller K., Kristiansen S., Phipps R., Nielsen A.K., Jensen P.Ø., et al. Silver against Pseudomonas aeruginosa biofilms. APMIS 115 (2007) 921-928
26. Anwar H., Dasgupta M.K., and Costerton J.W. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 34 (1990) 2043-2046
27. Domingue G., Ellis B., Dasgupta M., and Costerton J.W. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards. J Clin Microbiol 32 (1994) 2564-2568
28. Costerton J.W., Lewandowski Z., Caldwell D.E., Korber D.R., and Lappinscott H.M. Microbial biofilms. Annu Rev Microbiol 49 (1995) 711-745
29. Werner E., Roe F., Bugnicourt A., Franklin M.J., Heydorn A., Molin S., et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 70 (2004) 6188-6196
30. Keren I., Kaldalu N., Spoering A., Wang Y.P., and Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230 (2004) 13-18
31. Yang L., Haagensen J.A.J., Jelsbak L., Johansen H.K., Sternberg C., Høiby N., et al. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infection. J Bacteriol 190 (2008) 2767-2776
32. Driffield K., Miller K., Bostock M., O'Neill A.J., and Chopra I. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 61 (2008) 1053-1056
33. Molin S., and Tolker-Nielsen T. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr Opin Biotechnol 14 (2003) 255-261
34. Høiby N., Johansen H.K., Moser C., Song Z.J., Ciofu O., and Kharazmi A. Pseudomonas aeruginosa and the biofilm mode of growth. Microbes Infect 3 (2001) 1-13
35. Oliver A., Canton R., Campo P., Baquero F., and Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288 (2000) 1251-1253
36. Ciofu O., Riis B., Pressler T., Poulsen H.E., and Høiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 49 (2005) 2276-2282
37. Oliver A., Sanchez J.M., and Blazquez J. Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiol Lett 217 (2002) 31-35
38. Mandsberg L.F., Ciofu O., Kirkby N., Christiansen L.E., Poulsen H.E., and Høiby N. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 53 (2009) 2483-2491
39. Macia M.D., Blanquer D., Togores B., Sauleda J., Perez J.L., and Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49 (2005) 3382-3386
40. Hassett D.J., Ma J.F., Elkins J.G., McDermott T.R., Ochsner U.A., West S.E.H., et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol 34 (1999) 1082-1093
41. Mai-Prochnow A., Lucas-Elio P., Egan S., Thomas T., Webb J., Sanchez-Amat A., et al. Hydrogen peroxide linked to lysine oxidase activity facilitates biofilm differentiation and dispersal in several Gram-negative bacteria. J Bacteriol 190 (2008) 5493-5501
42. Conibear T.C., Collins S.L., and Webb J.S. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS One 14 (2009) e6289
43. Boles B.R., and Singh P.K. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 105 (2008) 12503-12508
44. Kolpen M., Hansen C.R., Bjarnsholt T., Moser C., Christensen L.D., van Gennip M., et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 65 (2010) 57-62
45. Ciofu O., Giwercman B., Pedersen S.S., and Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 102 (1994) 674-680
46. Ciofu O. Pseudomonas aeruginosa chromosomal β-lactamase in patients with cystic fibrosis and chronic lung infection-mechanism of antibiotic resistance and target of the humoral immune response. APMIS 111 (2003) 4-47
47. Jalal S., Ciofu O., Høiby N., Gotoh N., and Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 44 (2000) 710-712 [Erratum in: Antimicrob Agents Chemother 2000;44:1410]
48. Islam S., Oh H., Jalal S., Ciofu O., Høiby N., and Wretlind B. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect 15 (2009) 60-66
49. Johansen H.K., Moskowitz S.M., Ciofu O., Pressler T., and Høiby N. Spread of colistin-resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7 (2008) 391-397
50. Giwercman B., Lambert P.A., Rosdahl V.T., Shand G.H., and Hoiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 26 (1990) 247-259
51. Nakae T., Nakajima A., Ono T., Saito K., and Yoneyama H. Resistance to β-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and β-lactamase. Antimicrob Agents Chemother 43 (1999) 1301-1303
52. Bagge N., Ciofu O., Hentzer M., Campbell J.I.A., Givskov M., and Hoiby N. Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother 46 (2002) 3406-3411
53. de Beer D., Stoodley P., and Lewandowski Z. Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnol Bioeng 53 (1997) 151-158
54. Dibdin G.H., Assinder S.J., Nichols W.W., and Lambert P.A. Mathematical model of β-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released β-lactamases. J Antimicrob Chemother 38 (1996) 757-769
55. Ciofu O., Beveridge T.J., Kadurugamuwa J., Walther-Rasmussen J., and Hoiby N. Chromosomal β-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother 45 (2000) 9-13
56. Giwercman B., Jensen E.T., Hoiby N., Kharazmi A., and Costerton J.W. Induction of β-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother 35 (1991) 1008-1010
57. Nichols W.W., Evans M.J., Slack M.P., and Walmsley H.L. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 135 (1989) 1291-1303
58. Giwercman B., Meyer C., Lambert P.A., Reinert C., and Hoiby N. High-level β-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother 36 (1992) 71-76
59. Bagge N., Hentzer M., Andersen J.B., Ciofu O., Givskov M., and Hoiby N. Dynamics and spatial distribution of β-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 48 (2004) 1168-1174
60. Hill D., Rose B., Pajkos A., Robinson M., Bye P., Bell S., et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43 (2005) 5085-5090
61. Ciofu O., and Høiby N. Cystic fibrosis-coping with resistance. In: Gould I., and van der Meer J. (Eds). Antibiotic policies-fighting resistance (2007), Springer Verlag, New York, NY 149-174
62. Bagge N., Schuster M., Hentzer M., Ciofu O., Givskov M., Greenberg E.P., et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 48 (2004) 1175-1187
63. Wood L.F., Leech A.J., and Ohman D.E. Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol 62 (2006) 412-426
64. Dunne W.M. Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci. Antimicrob Agents Chemother 34 (1990) 390-393
65. Permin H., Koch C., Høiby N., Christensen H.O., Møller A.F., and Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 12 Suppl A (1983) 313-323
66. Anwar H., Strap J.L., and Costerton J.W. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother 36 (1992) 1347-1351
67. Levy J., Smith A.L., Kenny M.A., Ramsey B., and Schoenknecht F.D. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 148 (1983) 1069-1076
68. Hunt B.E., Weber A., Berger A., Ramsey B., and Smith A.L. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 39 (1995) 34-39
69. Walters M.C., Roe F., Bugnicourt A., Franklin M.J., and Stewart P.S. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47 (2003) 317-323
70. Alipour M., Suntres Z.E., and Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 64 (2009) 317-325
71. Pamp S.J., Gjermansen M., Johansen H.K., and Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the prm and mexAB-oprM genes. Mol Microbiol 68 (2008) 223-240
72. Haagensen J., Klausen M., Ernst R.K., Miller S.I., Folkesson A., Tolker-Nielsen T., et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 189 (2007) 28-37
73. Hansen C.R., Pressler T., and Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7 (2008) 523-530
74. Bjarnsholt T., Jensen P.-Ø., Burmølle M., Hentzer M., Haagensen J.A.J., Hougen H.P., et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151 (2005) 373-383
75. Greenberg E.P. Quorum sensing in Gram-negative bacteria. ASM News 63 (1997) 371-377
76. Lindum P.W., Anthoni U., Christophersen C., Eberl L., Molin S., and Givskov M. N-acyl-l-homoserine lactone autoinducers control production of an extracellular lipopeptide biosurfactant required for swarming motility of Serratia liquefaciens MG1. J Bacteriol 180 (1998) 6384-6388
77. Williams P., Camara M., Hardman A., Swift S., Milton D., Hope V.J., et al. Quorum sensing and the population-dependent control of virulence. Philos Trans R Soc Lond B Biol Sci 355 (2000) 667-680
78. Bjarnsholt T., and Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem 387 (2007) 409-414
79. Jensen P.Ø., Bjarnsholt T., Phipps R., Rasmussen T.B., Calum H., Christoffersen L., et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153 (2007) 1329-1338
80. Van Gennip M., Christensen L.D., Alhede M., Phipps R., Jensen P.Ø., Christophersen L., et al. Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS 117 (2009) 537-546
81. Alhede M., Bjarnsholt T., Jensen P.Ø., Phipps R.K., Moser C., Christophersen L., et al. Pseudomonas aeruginosa recognizes and responds agressively to the presence of polymorphonuclear leukocytes. Microbiology 155 (2009) 3500-3508
82. Davies D.G., Parsek M.R., Pearson J.P., Iglewski B.H., Costerton J.W., and Greenberg E.P. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280 (1998) 295-298
83. Parsek M.R., and Greenberg E.P. Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol 13 (2005) 27-33
84. Hentzer M., Wu H., Andersen J.B., Riedel K., Rasmussen T.B., Bagge N., et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 22 (2003) 3803-3815
85. Givskov M., de Nys R., Manefield M., Gram L., Maximilien R., Eberl L., et al. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J Bacteriol 178 (1996) 6618-6622
86. Rasmussen T.B., Bjarnsholt T., Skindersoe M.E., Hentzer M., Kristoffersen P., Köte M., et al. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol 187 (2005) 1799-1814
87. Wu H., Song Z.J., Hentzer M., Andersen J.B., Heydorn A., Mathee K., et al. Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology 146 (2000) 2481-2493
88. Hentzer M., and Givskov M. Pharmacological inhibition of quorum sensing for treatment of chronic bacterial infections. J Clin Invest 112 (2003) 1300-1307
89. -/- mice. Antimicrob Agents Chemother 51 (2007) 3677-3687
90. Skindersøe M.E., Alhede M., Phipps R., Yang L., Jensen P.O., Rasmussen T.B., et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52 (2008) 3548-3663
91. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57 (2002) 212-216
92. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
93. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
94. Hansen C.R., Pressler T., Koch C., and Høiby N. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 4 (2005) 35-40
95. Tramper-Stranders G.A., Wolfs T.F.W., Fleer A., Kimpen J.L.L., and van der Ent C.K. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26 (2007) 8-12
96. Bjarnsholt T., Jensen P.Ø., Rasmussen T.B., Christophersen L., Calun H., Hentzer M., et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 151 (2005) 3873-3880
97. Lee B., Haagensen J.A.J., Ciofu O., Andersen J.B., Høiby N., and Molin S. Heterogeneity of biofilms formed by non-mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 43 (2005) 5247-5255
98. Costerton J.W., Stewart P.S., and Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 284 (1999) 1318-1322
99. Stensballe J., Tvede M., Loorns D., Lippert F.K., Dahl B., Tønnesen E., et al. Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients. Ann Intern Med 147 (2007) 285-293
100. Reid G. Biofilms in infectious disease and on medical devices. Int J Antimicrob Agents 11 (1999) 223-226
101. Høiby N., and Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 78 (1989) 395-404
102. Döring G., and Høiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 3 (2004) 67-91
103. ®) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 95 (2006) 1070-1074
104. Baumann U., Stocklossa C., Greiner W., von der Schulenburg J.M., and von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2 (2003) 84-90
105. Frederiksen B., Koch C., and Høiby N. The changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients, 1974-1995. Pediatr Pulmonol 28 (1999) 159-166
106. van Gennip M., Moser C., Christensen L.D., Bjarnsholt T., Calum H., Jensen P.Ø., et al. Augmented effect of early antibiotic therapy in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. J Antimicrob Chemother 64 (2009) 1241-1250
107. Döring G., and Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26 (2008) 1011-1024
108. Doring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Hoiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
109. Høiby N., Flensborg E.W., Beck B., Friis B., Jacobsen L., and Jacobsen S.V. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis 58 (1977) 65-79
110. Proesmans M., Balinska-Miskiewicz W., Dupont L., Bossuyt X., Verhaegen J., Høiby N., et al. Evaluating the 'Leeds criteria' for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 27 (2006) 937-943
111. Frederiksen B., Lanng S., Koch C., and Høiby N. Improved survival in the Danish cystic fibrosis centre: results of aggressive treatment. Pediatr Pulmonol 21 (1996) 153-158
112. Koch C., Hjelt K., Pedersen S.S., Jensen E.T., Jensen T., Lanng S., et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other β-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 13 Suppl 7 (1991) S608-S611